Study of IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Recruiting

Phase 1

Phase 2

Study of IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC FusionsStudy of IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Sponsor:

IDEAYA Biosciences

Code:

NCT03947385

Conditions

Metastatic Uveal Melanoma

Cutaneous Melanoma

Colorectal Cancer

Other Solid Tumors

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

IDE196

Binimetinib

Crizotinib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-28. This information was provided to ClinicalTrials.gov by IDEAYA Biosciences on 2024-11-13.